betamethasone valerate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
prednisone and prednisolone derivatives 354 2152-44-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • betamethasone valerate
  • bextasol
  • celeston valerate
  • valisone
  • bedermin
Betamethasone valerate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
  • Molecular weight: 476.59
  • Formula: C27H37FO6
  • CLOGP: 3.91
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 100.90
  • ALOGS: -4.85
  • ROTB: 7
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
S (Water solubility) 0.06 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 3.154 Moderate 0.77
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.074 Moderate 0.77
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 72.946 10^-6 cm/s Moderate 0.77
dh-clint Dog hepatocyte intrinsic clearance 17.947 uL/min/10^6 cells Moderate 0.77
dppb Dog plasma protein binding (% unbound) 5.020 % Moderate 0.77
fcs-ppb Fetal calf serum protein binding (% unbound) 9.760 % Moderate 0.77
herg hERG pIC50 4.649 pIC50 Moderate 0.77
hh-clint Human hepatocyte intrinsic clearance 28.184 uL/min/10^6 cells Moderate 0.77
hlm-clint Human liver microsomal intrinsic clearance 142.561 uL/min/mg protein Moderate 0.77
hppb Human plasma protein binding (% unbound) 6.320 % Moderate 0.77
kinase-safety-class ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,TEK,TGFBR1 21
kinase-selectivity-class AXL,GRK2,MAP2K6 3
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 6.339 Moderate 0.73
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 4.406 Moderate 0.77
mh-clint Mouse hepatocyte intrinsic clearance 55.719 Moderate 0.77
mppb Mouse plasma protein binding (% unbound) 5.900 Moderate 0.77
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 15.453 Moderate 0.77
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 Moderate 0.73
pppb Pig plasma protein binding (% unbound) 13.460 % Moderate 0.77
rat-kpuu-brain Rat brain Kpuu 0.058 % Moderate 0.73
rh-clint Rat hepatocyte intrinsic clearance 112.202 uL/min/10^6 cells Moderate 0.77
rh-fuinc Rat hepatocyte fraction unbound in incubation 43.530 % Moderate 0.77
rppb Rat plasma protein binding (% unbound) 5.040 % Moderate 0.77
solubility-dd Solubility at pH 7.4 in DMSO 90.782 uM Moderate 0.77

Approvals:

DateAgencyCompanyOrphan
Sept. 2, 1967 FDA SCHERING

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 866.80 15.27 329 21127 37641 90569350
Chronic sinusitis 388.30 15.27 162 21294 23640 90583351
Vaginal flatulence 344.89 15.27 125 21331 12513 90594478
Proctitis 321.95 15.27 125 21331 15134 90591857
Female genital tract fistula 313.04 15.27 128 21328 17740 90589251
Radiculopathy 301.96 15.27 126 21330 18379 90588612
Paraesthesia oral 301.43 15.27 148 21308 31511 90575480
Vaginal discharge 292.51 15.27 125 21331 19339 90587652
Oral candidiasis 251.56 15.27 136 21320 35319 90571672
Procedural pain 242.37 15.27 130 21326 33230 90573761
Rectal haemorrhage 213.13 15.27 168 21288 82576 90524415
Haematochezia 206.76 15.27 155 21301 70758 90536233
Colitis ulcerative 192.06 15.27 139 21317 60127 90546864
Frequent bowel movements 182.99 15.27 132 21324 56803 90550188
Colitis 171.51 15.27 138 21318 69804 90537187
Blepharospasm 139.32 15.27 111 21345 55334 90551657
Taste disorder 131.21 15.27 112 21344 61434 90545557
Therapeutic product effect incomplete 126.28 15.27 190 21266 193706 90413285
Psoriasis 123.22 15.27 163 21293 147591 90459400
Erythema 114.32 15.27 199 21257 229047 90377944
Epilepsy 108.97 15.27 115 21341 82091 90524900
Weight decreased 104.48 15.27 258 21198 379652 90227339
Heart sounds 97.54 15.27 27 21429 1117 90605874
Drug ineffective 96.70 15.27 607 20849 1383691 89223300
Prolonged expiration 95.03 15.27 27 21429 1230 90605761
Blood pressure inadequately controlled 87.00 15.27 38 21418 6186 90600805
Depressed mood 86.42 15.27 81 21375 50141 90556850
Dyspepsia 85.99 15.27 162 21294 197998 90408993
Migraine 76.89 15.27 151 21305 190241 90416750
Exercise tolerance decreased 73.91 15.27 36 21420 7515 90599476
Multiple drug therapy 64.38 15.27 32 21424 6977 90600014
Acute motor-sensory axonal neuropathy 62.04 15.27 15 21441 360 90606631
Gastrooesophageal reflux disease 58.93 15.27 125 21331 166212 90440779
Abdominal pain 58.47 15.27 216 21240 395505 90211486
Depressive symptom 57.20 15.27 27 21429 5258 90601733
Diabetes mellitus inadequate control 54.75 15.27 41 21415 18643 90588348
Pain 53.82 15.27 411 21045 995930 89611061
Malaise 53.72 15.27 277 21179 585709 90021282
Abdominal pain upper 52.87 15.27 186 21270 332488 90274503
Pyrexia 52.33 15.27 300 21156 660185 89946806
Respiration abnormal 52.17 15.27 29 21427 7934 90599057
Paraesthesia 51.58 15.27 153 21303 250173 90356818
Toxic shock syndrome 50.98 15.27 16 21440 1028 90605963
Endocrine ophthalmopathy 50.53 15.27 16 21440 1058 90605933
Memory impairment 49.96 15.27 130 21326 197114 90409877
Sleep disorder due to a general medical condition 49.57 15.27 57 21399 44681 90562310
Drug interaction 47.68 15.27 5 21451 276448 90330543
Death 46.65 15.27 25 21431 456526 90150465
Appetite disorder 45.89 15.27 28 21428 9105 90597886
Fatigue 43.49 15.27 135 21321 1153888 89453103
Constipation 42.16 15.27 154 21302 280241 90326750
Eyelid disorder 39.30 15.27 16 21440 2187 90604804
Nasal ulcer 36.36 15.27 16 21440 2650 90604341
Hypotension 35.98 15.27 16 21440 325381 90281610
Steroid withdrawal syndrome 35.70 15.27 11 21445 665 90606326
Rales 34.11 15.27 29 21427 15798 90591193
Total cholesterol/HDL ratio abnormal 34.07 15.27 7 21449 77 90606914
Skin plaque 34.02 15.27 24 21432 9951 90597040
Hepatic enzyme increased 33.66 15.27 22 21434 360714 90246277
Lip swelling 31.21 15.27 42 21414 38568 90568423
Flank pain 31.14 15.27 30 21426 19192 90587799
Spondylitis 30.60 15.27 26 21430 14152 90592839
Mean cell haemoglobin increased 30.55 15.27 16 21440 3889 90603102
Acute kidney injury 29.26 15.27 20 21436 320367 90286624
Rash pustular 28.93 15.27 20 21436 8029 90598962
Glossodynia 28.19 15.27 21 21435 321758 90285233
Swelling of eyelid 28.12 15.27 17 21439 5437 90601554
Angina pectoris 27.77 15.27 40 21416 39120 90567871
Skin atrophy 25.37 15.27 16 21440 5513 90601478
Weaning failure 25.31 15.27 8 21448 526 90606465
Thrombocytopenia 25.13 15.27 9 21447 208716 90398275
Nasal mucosal discolouration 25.05 15.27 5 21451 47 90606944
Narrow anterior chamber angle 24.86 15.27 5 21451 49 90606942
Groin infection 24.58 15.27 8 21448 578 90606413
Vulval cancer stage III 24.39 15.27 4 21452 10 90606981
Product dose omission issue 24.33 15.27 20 21436 291667 90315324
Hand deformity 23.89 15.27 21 21435 296341 90310650
Anhidrosis 23.34 15.27 6 21450 186 90606805
Concussion 23.24 15.27 20 21436 11071 90595920
Dyslipidaemia 22.77 15.27 19 21437 10088 90596903
Arthralgia 22.72 15.27 101 21355 778421 89828570
Hypoaesthesia 21.76 15.27 138 21318 314072 90292919
Pulmonary embolism 20.99 15.27 3 21453 130817 90476174
Paraneoplastic rash 20.37 15.27 5 21451 128 90606863
Respiratory disorder 19.87 15.27 46 21410 64770 90542221
Wrong technique in device usage process 19.81 15.27 14 21442 5821 90601170
Skin exfoliation 19.52 15.27 47 21409 67866 90539125
X-ray abnormal 19.49 15.27 37 21419 45387 90561604
Infusion related reaction 18.61 15.27 165 21291 416615 90190376
Anaemia 18.59 15.27 145 21311 352657 90254334
Helicobacter infection 18.36 15.27 16 21440 226834 90380157
Intertrigo 18.29 15.27 7 21449 813 90606178
Vitamin D decreased 18.11 15.27 18 21438 11961 90595030
Wound necrosis 17.85 15.27 6 21450 479 90606512
Pruritus 17.71 15.27 201 21255 541324 90065667
Productive cough 17.68 15.27 49 21407 77014 90529977
Product temperature excursion issue 17.64 15.27 7 21449 896 90606095
Increased bronchial secretion 17.35 15.27 9 21447 2144 90604847
Contraindicated product administered 17.13 15.27 31 21425 320108 90286883
Pain of skin 16.99 15.27 20 21436 16062 90590929
Systemic lupus erythematosus 16.84 15.27 38 21418 361858 90245133
Disease progression 16.83 15.27 8 21448 156607 90450384
Cutaneous T-cell lymphoma 16.69 15.27 8 21448 1612 90605379
Somnolence 16.62 15.27 15 21441 209069 90397922
Stevens-Johnson syndrome 16.59 15.27 27 21429 29349 90577642
Synovial cyst 16.56 15.27 17 21439 11735 90595256
Nasal congestion 16.22 15.27 50 21406 83364 90523627
Treatment noncompliance 16.17 15.27 37 21419 51690 90555301
Retinitis 16.10 15.27 31 21425 38427 90568564
Stress 16.02 15.27 49 21407 81346 90525645
Musculoskeletal stiffness 15.60 15.27 29 21427 296503 90310488
Anaemia macrocytic 15.59 15.27 11 21445 4561 90602430
Red blood cell sedimentation rate increased 15.59 15.27 49 21407 82546 90524445
Eye infection 15.51 15.27 18 21438 14236 90592755
Confusional state 15.30 15.27 44 21412 386161 90220830
Anal injury 15.29 15.27 4 21452 133 90606858

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 89.85 17.64 62 5129 48542 42567602
Pruritus 69.09 17.64 99 5092 188672 42427472
Rash 59.19 17.64 114 5077 276840 42339304
Eczema 41.74 17.64 34 5157 34052 42582092
Pain of skin 35.33 17.64 18 5173 8062 42608082
Blister 34.87 17.64 28 5163 27462 42588682
Rash erythematous 29.14 17.64 27 5164 32064 42584080
Inappropriate schedule of product administration 28.85 17.64 46 5145 95856 42520288
Prurigo 28.70 17.64 8 5183 668 42615476
Psoriasis area severity index increased 25.63 17.64 5 5186 85 42616059
Pneumonia haemophilus 25.12 17.64 8 5183 1056 42615088
Skin candida 24.34 17.64 7 5184 654 42615490
Genital herpes 23.36 17.64 7 5184 755 42615389
Psoriatic arthropathy 22.65 17.64 21 5170 24946 42591198
Arthralgia 21.31 17.64 64 5127 205174 42410970
Pain in jaw 21.05 17.64 16 5175 14486 42601658
Dermatitis atopic 20.96 17.64 15 5176 12389 42603755
Gingival blister 19.93 17.64 4 5187 79 42616065
Body surface area increased 19.15 17.64 4 5187 97 42616047
Exercise lack of 18.21 17.64 4 5187 124 42616020
Enteritis infectious 18.14 17.64 7 5184 1624 42614520
Oropharyngeal candidiasis 17.94 17.64 6 5185 923 42615221
Neuropsychiatric syndrome 17.91 17.64 4 5187 134 42616010

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Chronic sinusitis 384.48 14.94 161 24743 24923 110539472
Macular degeneration 382.98 14.94 154 24750 21505 110542890
Vaginal flatulence 352.00 14.94 124 24780 12020 110552375
Female genital tract fistula 325.40 14.94 127 24777 16392 110548003
Paraesthesia oral 314.71 14.94 153 24751 33518 110530877
Proctitis 311.89 14.94 124 24780 16803 110547592
Vaginal discharge 305.13 14.94 124 24780 17784 110546611
Radiculopathy 299.29 14.94 125 24779 19211 110545184
Procedural pain 243.41 14.94 131 24773 35434 110528961
Oral candidiasis 230.90 14.94 137 24767 44623 110519772
Colitis ulcerative 180.01 14.94 145 24759 77218 110487177
Rectal haemorrhage 177.71 14.94 174 24730 119659 110444736
Psoriasis 172.60 14.94 184 24720 139809 110424586
Frequent bowel movements 170.77 14.94 136 24768 71254 110493141
Haematochezia 158.84 14.94 161 24743 115363 110449032
Colitis 143.21 14.94 144 24760 102179 110462216
Therapeutic product effect incomplete 116.95 14.94 193 24711 223612 110340783
Erythema 109.79 14.94 218 24686 291229 110273166
Dyspepsia 108.38 14.94 171 24733 190794 110373601
Heart sounds 98.90 14.94 27 24877 1116 110563279
Weight decreased 97.62 14.94 278 24626 467779 110096616
Depressed mood 95.16 14.94 91 24813 60718 110503677
Blepharospasm 91.41 14.94 85 24819 54766 110509629
Prolonged expiration 90.74 14.94 27 24877 1525 110562870
Taste disorder 85.96 14.94 89 24815 65298 110499097
Blood pressure inadequately controlled 84.50 14.94 39 24865 7594 110556801
Pain 81.85 14.94 427 24477 954528 109609867
Malaise 71.59 14.94 320 24584 671499 109892896
Epilepsy 65.67 14.94 96 24808 100113 110464282
Death 64.25 14.94 39 24865 698830 109865565
Drug interaction 60 14.94 19 24885 500164 110064231
Multiple drug therapy 58.97 14.94 31 24873 7983 110556412
Hypotension 57.55 14.94 23 24881 523826 110040569
Acute motor-sensory axonal neuropathy 57.41 14.94 15 24889 523 110563872
Abdominal pain 57.34 14.94 248 24656 512741 110051654
Exercise tolerance decreased 57.19 14.94 35 24869 12032 110552363
Sleep disorder due to a general medical condition 51.33 14.94 61 24843 52051 110512344
Pruritus 48.91 14.94 259 24645 581301 109983094
Respiration abnormal 47.89 14.94 29 24875 9780 110554615
Endocrine ophthalmopathy 47.46 14.94 16 24888 1357 110563038
Pyrexia 47.43 14.94 355 24549 897910 109666485
Depressive symptom 46.64 14.94 27 24877 8387 110556008
Toxic shock syndrome 45.86 14.94 16 24888 1504 110562891
Appetite disorder 45.44 14.94 28 24876 9741 110554654
Migraine 44.85 14.94 111 24793 171541 110392854
Acute kidney injury 41.76 14.94 49 24855 635381 109929014
Diabetes mellitus inadequate control 39.97 14.94 41 24863 29734 110534661
Eyelid disorder 38.72 14.94 16 24888 2389 110562006
Nasal ulcer 37.59 14.94 16 24888 2571 110561824
Gastrooesophageal reflux disease 37.49 14.94 107 24797 179869 110384526
Pain of skin 37.20 14.94 33 24871 19996 110544399
Constipation 36.92 14.94 169 24735 357617 110206778
Spondylitis 36.90 14.94 26 24878 11312 110553083
Lip swelling 36.81 14.94 51 24853 50616 110513779
Skin atrophy 36.21 14.94 21 24883 6543 110557852
Skin plaque 34.36 14.94 26 24878 12619 110551776
Total cholesterol/HDL ratio abnormal 34.33 14.94 7 24897 78 110564317
Swelling of eyelid 33.33 14.94 20 24884 6633 110557762
Rash pustular 31.85 14.94 25 24879 12804 110551591
Memory impairment 30.79 14.94 106 24798 196838 110367557
Eczema 30.74 14.94 57 24847 72236 110492159
Paraesthesia 29.54 14.94 132 24772 276389 110288006
Infusion related reaction 28.79 14.94 165 24739 380997 110183398
Steroid withdrawal syndrome 28.71 14.94 10 24894 935 110563460
Mean cell haemoglobin increased 28.44 14.94 17 24887 5600 110558795
Flank pain 27.75 14.94 30 24874 23100 110541295
Thrombocytopenia 27.37 14.94 23 24881 348862 110215533
Drug ineffective 25.62 14.94 482 24422 1520058 109044337
Skin exfoliation 25.37 14.94 59 24845 87592 110476803
Abdominal pain upper 24.98 14.94 149 24755 348962 110215433
Therapeutic response decreased 24.76 14.94 62 24842 96437 110467958
Contusion 24.62 14.94 111 24793 233250 110331145
Vulval cancer stage III 24.59 14.94 4 24900 10 110564385
Overdose 24.46 14.94 11 24893 233783 110330612
Rales 24.42 14.94 29 24875 24710 110539685
X-ray abnormal 24.21 14.94 36 24868 38081 110526314
Headache 23.34 14.94 302 24602 882075 109682320
Disease progression 23.25 14.94 13 24891 244021 110320374
Product dose omission issue 23.12 14.94 23 24881 321759 110242636
Nasal mucosal discolouration 23.09 14.94 5 24899 76 110564319
Drug abuse 22.60 14.94 6 24898 177405 110386990
Weaning failure 22.18 14.94 8 24896 828 110563567
Dermatitis atopic 22.08 14.94 28 24876 25513 110538882
Red blood cell sedimentation rate increased 21.89 14.94 52 24852 78250 110486145
Rash 21.71 14.94 281 24623 820683 109743712
Concussion 21.41 14.94 19 24885 11519 110552876
Retinitis 21.21 14.94 31 24873 32296 110532099
Vitamin D decreased 20.48 14.94 19 24885 12196 110552199
Renal failure 20.28 14.94 13 24891 226561 110337834
Groin infection 20.26 14.94 8 24896 1062 110563333
Fatigue 20.23 14.94 176 24728 1215782 109348613
Skin disorder 19.72 14.94 35 24869 42878 110521517
Cardiac failure congestive 19.44 14.94 5 24899 150995 110413400
Feeding disorder 19.39 14.94 24 24880 21338 110543057
Seronegative arthritis 19.25 14.94 19 24885 13158 110551237
Narrow anterior chamber angle 19.17 14.94 5 24899 173 110564222
Anhidrosis 19.14 14.94 6 24898 404 110563991
Hepatic enzyme increased 18.72 14.94 27 24877 320865 110243530
Stevens-Johnson syndrome 18.72 14.94 36 24868 46865 110517530
Stress 18.50 14.94 59 24845 105289 110459106
Product temperature excursion issue 18.38 14.94 7 24897 844 110563551
Wrong technique in device usage process 18.33 14.94 14 24890 6887 110557508
Prurigo 18.19 14.94 8 24896 1392 110563003
Nasal congestion 18.14 14.94 56 24848 98226 110466169
Angina pectoris 18.10 14.94 42 24862 62253 110502142
Dyslipidaemia 17.92 14.94 20 24884 15945 110548450
Condition aggravated 17.86 14.94 95 24809 734741 109829654
Enteritis infectious 17.73 14.94 11 24893 3871 110560524
Synovial cyst 17.67 14.94 17 24887 11413 110552982
General physical health deterioration 17.61 14.94 44 24860 425251 110139144
Respiratory disorder 17.42 14.94 45 24859 71337 110493058
Upper respiratory tract infection 17.39 14.94 67 24837 131261 110433134
Lipohypertrophy 17.24 14.94 7 24897 999 110563396
Hypoxia 17.23 14.94 4 24900 129511 110434884
Psoriasis area severity index increased 16.67 14.94 5 24899 290 110564105
Cardio-respiratory arrest 16.61 14.94 3 24901 115833 110448562
Eye infection 15.98 14.94 18 24886 14500 110549895
Sepsis 15.90 14.94 31 24873 327315 110237080
Intertrigo 15.84 14.94 7 24897 1231 110563164
Rash macular 15.82 14.94 30 24874 38656 110525739
Pneumonia haemophilus 15.82 14.94 9 24895 2706 110561689
Asthenia 15.69 14.94 91 24813 688908 109875487
Wound necrosis 15.45 14.94 6 24898 762 110563633
Plantar fasciitis 15.00 14.94 11 24893 5090 110559305

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA MoA N0000175450 Corticosteroid Hormone Receptor Agonists
FDA EPC N0000175576 Corticosteroid
CHEBI has role CHEBI:35472 anti-inflammatory drug
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35705 immunosuppressive agent
CHEBI has role CHEBI:35845 gout suppressant
CHEBI has role CHEBI:39456 antiglaucoma drug
CHEBI has role CHEBI:49201 anti-ulcer drug
CHEBI has role CHEBI:50177 dermatologic drug
CHEBI has role CHEBI:50748 antipsoriatic
CHEBI has role CHEBI:51177 antitussive
CHEBI has role CHEBI:65023 anti-asthmatic agent
CHEBI has role CHEBI:66981 ophthalmology drug
CHEBI has role CHEBI:77715 nasal decongestant
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D005938 Glucocorticoids
MeSH PA D006728 Hormones
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D019141 Respiratory System Agents
CHEBI has role CHEBI:233423 antifibrotic agent

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Atopic dermatitis indication 24079001 DOID:3310
Contact dermatitis indication 40275004 DOID:2773
Seborrheic dermatitis indication 50563003 DOID:8741
Lichen simplex chronicus indication 53891004
Granuloma annulare indication 65508009 DOID:3777
Pruritus ani indication 90446007
Discoid lupus erythematosus indication 200938002
Plaque psoriasis indication 200965009
Scalp psoriasis indication 238608008
Pruritus of genital organs indication 267802000
Eruption of skin indication 271807003 DOID:0050486
Primary cutaneous T-cell lymphoma indication 400122007
Dermatosis of scalp indication 402694007 DOID:3136
Telangiectasia disorder contraindication 247479008
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Atrophoderma contraindication 399979006
Peripheral vascular disease contraindication 400047006




🐶 Veterinary Drug Use

SpeciesUseRelation
Cats Pruritus associated with dermatoses Indication
Dogs Pruritus associated with dermatoses Indication
Horses Inflammatory joint conditions Indication

🐶 Veterinary products

ProductApplicantIngredients
Gentocin Otic Solution Intervet Inc. 2
Topagen Ointment Intervet Inc. 2
Gentocin Topical Spray Intervet Inc. 2
Otomax Intervet Inc. 3
VET BETA-GEN Med-Pharmex Inc. 2
Betagen Topical Spray Med-Pharmex Inc. 2
Tri-Otic Ointment Med-Pharmex Inc. 3
Vetro-Max Fougera Pharmaceuticals Inc. 3
GBC Ointment Cronus Pharma Specialities India Private Limited 3
GB Topical Spray Dechra Veterinary Products LLC 2
Gentamicin Sulfate Topical Spray First Priority Inc. 2
Gentamicin Topical Spray Sparhawk Laboratories Inc. 2

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.24 acidic
pKa2 11.86 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Glucocorticoid receptor Nuclear hormone receptor AGONIST CHEMBL CHEMBL

External reference:

IDSource
4018643 VUID
N0000167463 NUI
D01357 KEGG_DRUG
1514 RXNORM
C0750848 UMLSCUI
CHEMBL1497 ChEMBL_ID
D001624 MESH_DESCRIPTOR_UI
9IFA5XM7R2 UNII
16533 PUBCHEM_CID
DB00443 DRUGBANK_ID
10006 MMSL
3225 MMSL
3226 MMSL
4270 MMSL
4278 MMSL
d00628 MMSL
C0005308 UMLSCUI
9782 PUBCHEM_CID
1045 INN_ID
4018643 VANDF
4018644 VANDF
D001623 MESH_DESCRIPTOR_UI
002168 NDDF
002173 NDDF
116571008 SNOMEDCT_US
29896003 SNOMEDCT_US
396005002 SNOMEDCT_US
CHEBI:3077 CHEBI
9IFA5XM7R2 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Betamethasone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 0168-0033 OINTMENT 1 mg TOPICAL NDA 18 sections
Betamethasone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 0168-0040 CREAM 1 mg TOPICAL NDA 18 sections
Betamethasone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 0168-0041 LOTION 1 mg TOPICAL NDA 18 sections
Betamethasone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 0713-0326 CREAM 1.20 mg TOPICAL NDA 18 sections
Betamethasone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 0713-0327 OINTMENT 1.20 mg TOPICAL ANDA 18 sections
BETAMETHASONE VALERATE HUMAN PRESCRIPTION DRUG LABEL 1 16590-034 CREAM 1 mg TOPICAL ANDA 12 sections
Betamethasone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 21695-584 CREAM 1 mg TOPICAL ANDA 20 sections
Betamethasone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 21695-586 OINTMENT 1 mg TOPICAL ANDA 20 sections
Betamethasone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 45802-053 AEROSOL, FOAM 1.20 mg TOPICAL ANDA 22 sections
Betamethasone valerate HUMAN PRESCRIPTION DRUG LABEL 1 46708-708 AEROSOL, FOAM 1.20 mg TOPICAL ANDA 11 sections
BETAMETHASONE VALERATE HUMAN PRESCRIPTION DRUG LABEL 1 50090-1647 CREAM 1 mg TOPICAL ANDA 20 sections
BETAMETHASONE VALERATE HUMAN PRESCRIPTION DRUG LABEL 1 50090-3134 CREAM 1 mg TOPICAL ANDA 21 sections
Betamethasone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 50090-3794 CREAM 1.20 mg TOPICAL NDA 18 sections
Betamethasone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 50090-4696 CREAM 1.20 mg TOPICAL NDA 18 sections
BETAMETHASONE VALERATE HUMAN PRESCRIPTION DRUG LABEL 1 51672-1269 CREAM 1 mg TOPICAL ANDA 21 sections
Betamethasone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 51672-4188 AEROSOL, FOAM 1.20 mg TOPICAL ANDA 23 sections
Betamethasone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 53002-8450 OINTMENT 1.20 mg TOPICAL ANDA 18 sections
Betamethasone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 53002-9210 CREAM 1 mg TOPICAL NDA 18 sections
BETAMETHASONE VALERATE HUMAN PRESCRIPTION DRUG LABEL 1 53002-9211 CREAM 1 mg TOPICAL ANDA 20 sections
Betamethasone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 54868-0520 CREAM 1 mg TOPICAL ANDA 19 sections
Betamethasone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 54868-2994 OINTMENT 1 mg TOPICAL ANDA 19 sections
Betamethasone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 54868-5002 LOTION 1 mg TOPICAL ANDA 19 sections
LUXIQ HUMAN PRESCRIPTION DRUG LABEL 1 54868-5424 AEROSOL, FOAM 1.20 mg TOPICAL NDA 20 sections
Betamethasone valerate HUMAN PRESCRIPTION DRUG LABEL 1 62332-708 AEROSOL, FOAM 1.20 mg TOPICAL ANDA 11 sections
Betamethasone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 66267-984 CREAM 1.20 mg TOPICAL ANDA 17 sections
Betamethasone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 67296-0573 CREAM 1 mg TOPICAL NDA 18 sections
Betamethasone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 67296-2080 OINTMENT 1.20 mg TOPICAL ANDA 18 sections
Betamethasone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 68071-2334 CREAM 1.20 mg TOPICAL NDA 17 sections
BETAMETHASONE VALERATE HUMAN PRESCRIPTION DRUG LABEL 1 68071-4278 CREAM 1 mg TOPICAL ANDA 21 sections
Betamethasone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 68071-5224 CREAM 1.20 mg TOPICAL NDA 18 sections